Home Biosimilar Antibodies Metabolism PCSK9 Bococizumab (Anti-PCSK9)
For research use only. Not for use in humans.

Bococizumab (Anti-PCSK9)

Synonyms: PF-04950615; RN316

Bococizumab (Anti-PCSK9) is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used for the treatment of hyperlipidemia. MW: 145.06 kD.

Bococizumab (Anti-PCSK9)

Quality Control

Batch: Purity: 99% Protein concentration: 9.527mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation PCSK9
PF-06446846 0
PF-06446846 hydrochloride 0
SBC-110736 0
R-IMPP 0
SBC-115076 9
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Bococizumab (Anti-PCSK9) is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used for the treatment of hyperlipidemia. MW: 145.06 kD.
References

Product Details

CAS No. 1407495-02-6
Molecular Weight 145.06
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07686796 NOT_YET_RECRUITING Drug: CAPOX (oxaliplatin/capecitabine)|Drug: Sintilimab|Drug Local Advanced Rectal Cancer; PD-1 Inhibitor; PCSK9 Inhibitor; RCT; Radiotherapy; Capecitabine; Oxaliplatin Guangdong Provincial People's Hospital 2027-01-01 PHASE3
NCT06381947 UNKNOWN Drug: Lipid-lowering therapy combination with PCSK9 inhibito Dyslipidemias; Statin Adverse Reaction; Cardiovascular Diseases; Lipid Metabolism Disorders University of Salerno 2024-05-01 PHASE4
NCT07253584 COMPLETED Drug: SAL003 140 mg|Drug: Placebo Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia Shenzhen Salubris Pharmaceuticals Co., Ltd. 2023-12-19 PHASE3
NCT07278830 COMPLETED Drug: SAL003 140mg+Atorvastatin|Drug: SAL003 420mg+Atorvasta Hypercholesterolemia and Mixed Dyslipidemia Shenzhen Salubris Pharmaceuticals Co., Ltd. 2023-06-02 PHASE2
NCT05128539 TERMINATED Drug: JS001(Toripalimab)+JS002 Advanced Cancer Shanghai Junshi Bioscience Co., Ltd. 2022-02-10 PHASE1
NCT05325203 COMPLETED Drug: Placebo Heterozygous Familial Hypercholesterolemia Shanghai Junshi Bioscience Co., Ltd. 2021-12-31 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-07-07)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.